'Ghostbusting' at Blood

Blood

Volumn 113, Issue 3, 2009, Pages 502-503

  Dunbar, Cynthia E ^a   Tallman, Martin S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DRUG INDUSTRY; EDITORIAL; MEDICAL EDUCATION; MEDICAL LITERATURE; MEDICAL RESEARCH; PRIORITY JOURNAL; PUBLICATION; CONFLICT OF INTEREST; STANDARD;

BIOMEDICAL RESEARCH; CONFLICT OF INTEREST; PERIODICALS AS TOPIC;

EID: 60249101992     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-10-184952     Document Type: Editorial

References (8)

1. Flanagin A, Carey LA, Fontanarosa PB, et al. Prevalence of articles with honorary authors and ghost authors in peer-reviewed medical journals. JAMA. 1998;280:222-224.
2. Mowatt G, Shirran L, Grimshaw JM, et al. Prevalence of honorary and ghost authorship in Cochrane reviews. JAMA. 2002;287:2769-2771.
3. Gotzsche PC, Hrobjartsson A, Johansen HK, Haahr MT, Altman DG, Chan AW. Ghost authorship in industry-initiated randomised trials. PLoS Med. 2007;4:e19.
4. Berenson A. Evidence in Vioxx suits shows intervention by Merck officials. NYTimes. 2005; April 24.
5. Daskalopoulou SS, Mikhailidis DP. The involvement of professional medical writers in medical publications [editorial]. Curr Med Res Opin. 2005; 21:307-310.
6. Lisse JR, Perlman M, Johansson G, et al. Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. Ann Intern Med. 2003;139:539-546.
7. Hill KP, Ross JS, Egilman DS, Krumholz HM. The ADVANTAGE seeding trial: a review of internal documents. Ann Intern Med. 2008;149: 251-258.
8. Ross JS, Hill KP, Egilman DS, Krumholz HM. Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA. 2008; 299:1800-1812.